drugset / Trial / NCT01033396

The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

NCT01033396 ↗

Phase 2 Completed 64 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Timeline

Start
2010-01
Primary completion
2010-05
Completion
2010-05

Outcome

Missed primary endpoint

paper PF-03654764 + fexofenadine was not superior to pseudoephedrine + fexofenadine. PMID 25024716 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 60 mg —
Subject PF-03654764 Small molecule 5 mg —
Comparator Pseudoephedrine Small molecule 120 mg —

Indications